Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00923598 · ClinicalTrials.gov registry record · Phase 4
Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT00923598 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 48 participants.
The verdict
NCT00923598, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a randomized, observer-masked, controlled study. Subjects will be patients undergoing bilateral total knee arthroplasty (TKA). One side (left or right) will be randomized to one of two treatment groups: a postoperative ropivacaine concentration of 0.1% or 0.4%. The contralateral side will receive the other possible ropivacaine concentration of 0.1% or 0.4%. The basal rate and patient-controlled bolus volume will depend upon the treatment group, but the total dose of local anesthetic is the same for each. For the duration of the study, all patients will receive the current usual and customary analgesics for bilateral TKA patients. All patients will receive a ropivacaine perineural infusions initiated in the operating room and continued until at least the afternoon of postoperative day (POD) 2, as well as oral acetaminophen, a sustained-release oral opioid; and celecoxib. Rescue opioid and route of administration will be determined by pain severity using a Numeric Rating Scale of 0-10, with 0 equal to no pain and 10 being the worst imaginable pain.
Interventions
- DRUG 0.1% and 0.4% perineural ropivicaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00923598
The ClinicalTrials.gov registry entry for NCT00923598 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 0.1% and 0.4% perineural ropivicaine is the first listed.
NCT00923598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00923598 about?
NCT00923598 is a clinical study titled "Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks". This is a randomized, observer-masked, controlled study. Subjects will be patients undergoing bilateral total knee arthroplasty (TKA). One side (left or right) will be randomized to one of two treatment groups: a postoperative ropivacaine concentration of 0.1% or 0.4%. The contralateral side will re...
What is the current status of trial NCT00923598?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2009-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00923598?
The interventions under investigation include: 0.1% and 0.4% perineural ropivicaine (DRUG).
Who is sponsoring clinical trial NCT00923598?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.